Healthcare IT strategy for medtech, pharma, and life sciences companies is governed primarily by FDA regulations, not by the HIPAA and ONC interoperability rules that shape health system technology decisions. The distinction matters because the regulatory framework determines which technology choices carry compliance risk, what validation looks like, how AI is governed, and what a technology strategy has to produce before a company can ship a product, conduct a clinical trial, or submit to a regulator.
This post explains what healthcare IT strategy looks like in medtech, pharma, and life sciences versus in health systems, where regulatory requirements diverge; what AI governance means in each context; and what Tristella brings to this work.
Why health system IT and life sciences IT are different problems
Most healthcare IT consulting is designed around health systems: hospitals, health plans, outpatient practices. The central technology in that world is the EHR. The regulatory framework is HIPAA, the ONC's interoperability rules, and CMS requirements for value-based care. The primary systems in scope are Epic and Cerner, HL7 FHIR APIs, patient engagement platforms, and clinical decision support tools. The questions a health system IT strategist most often answers concern workflow integration, interoperability, and care delivery efficiency.
Medtech and pharmaceutical companies operate under a completely different regulatory structure. Their primary regulator is the FDA, not ONC or CMS. The technology decisions that carry the most regulatory risk are not EHR integrations. They are the software embedded in or connected to medical devices, the validated computer systems supporting drug manufacturing and clinical trials, and the AI/ML models embedded in products that diagnose or treat patients.
These are not just different compliance checklists. They represent different frameworks for how technology is designed, validated, documented, and changed over time. A technology strategist who knows Epic implementation cold may have little useful to say about an IND-enabling systems strategy or a Predetermined Change Control Plan for an AI-enabled medical device. The domains require different expertise, and the gaps in the wrong direction create real regulatory and business risk.
Medtech IT strategy: software as a regulated product
In medtech, software is often the product or a regulated part of it. The FDA's Software as a Medical Device (SaMD) framework applies to any software intended to perform a medical function without being part of a physical device, and increasingly, to software functions embedded in connected devices, diagnostic platforms, and AI-enabled clinical decision support tools.
The pathway to market for a medical device with significant software components depends on how the FDA classifies the device's risk level. A Class I device (low risk) may be exempt from premarket review. A Class II device typically requires a 510(k) submission demonstrating substantial equivalence to a legally marketed predicate. A Class III device, or one with no predicate, requires a Premarket Approval (PMA) or De Novo classification request, accompanied by clinical evidence of safety and effectiveness.
What this means for technology strategy: software design decisions made early in a product's development have direct consequences for the regulatory pathway, the documentation burden, and the timeline to market. A software architecture that complicates the substantial equivalence argument for a 510(k) is not just a technical problem. It is a market timing problem. A technology strategy that does not account for the regulatory pathway from the start creates expensive course corrections later.
The quality and lifecycle standards governing medical device software differ from those for general software engineering. IEC 62304, the international standard for medical device software lifecycle processes, defines the documentation, verification, testing, and change management requirements that a software development process must meet for a regulated device. ISO 14971 governs risk management for medical devices, requiring a systematic process for identifying, evaluating, and controlling software-related risks. ISO 13485 governs the quality management system that frames all of this work.
These standards do not replace good engineering practice. They formalize it in ways that create an auditable record for the FDA's review. A technology strategy for a medtech company must account for these requirements across the product roadmap, development toolchain, test documentation, and change management process, as all of it is subject to review.
AI in medtech: the Predetermined Change Control Plan and why it changes everything
For medtech companies deploying AI or machine learning in their products, the FDA's approach to AI-enabled medical devices introduces a framework that has no parallel in general enterprise AI governance: the Predetermined Change Control Plan (PCCP).
The FDA's fundamental challenge with AI/ML-enabled medical devices is that these models can change their behavior as they learn from new data, which is precisely the feature that makes them clinically useful and also the feature that creates regulatory complexity. The traditional approach, in which a cleared or approved device must undergo new regulatory review before making significant changes, is not compatible with how adaptive AI systems are designed to work.
The PCCP framework, finalized by FDA in 2023, addresses this by allowing a manufacturer to describe, in advance, what changes the AI model may undergo and how those changes will be controlled, tested, and validated before implementation. FDA can review and authorize the change control plan as part of the original submission, allowing certain model updates to proceed under that plan without a new 510(k) or PMA supplement.
For a technology strategist, the PCCP has major implications. The architecture of an AI-enabled medical device has to be designed with the PCCP in mind from the start. The model update process, the validation methodology, the performance monitoring infrastructure, and the retraining cadence all need to be specified in a way that FDA can review. A post hoc attempt to create a PCCP for a system not designed with it in mind is significantly harder than building it into the original design.
As of early 2026, the FDA has authorized more than 950 AI/ML-enabled medical devices for market. The pace of authorization has accelerated each year. For medtech companies with AI on their product roadmap, understanding what the FDA expects of PCCP design is now a technology-strategy question, not just a regulatory-affairs question.
Pharma IT strategy: validation, Part 11, and the clinical data chain
Pharmaceutical technology strategy is shaped by a different set of FDA regulations, primarily 21 CFR Part 11 and the GxP framework (Good Manufacturing Practice, Good Clinical Practice, Good Laboratory Practice), along with the international standards that harmonize these requirements globally, including ICH E6 for Good Clinical Practice and EU Annex 11 for computerized systems.
21 CFR Part 11 governs electronic records and electronic signatures used in FDA-regulated activities. Any system that creates, modifies, maintains, archives, retrieves, or transmits records required by FDA predicate rules must comply with Part 11 requirements: audit trails that capture who changed what and when, access controls tied to individual accountability, system validation documentation, and controls to prevent unauthorized record modification. A clinical data management system, an eTMF, a LIMS, a regulatory submission platform: all of these carry Part 11 requirements, and a technology selection or implementation decision that overlooks them creates remediation costs that dwarf the original project budget.
GxP validation is the computer system validation (CSV) discipline that ensures systems used in GxP-regulated activities are fit for their intended purpose and perform consistently and reliably. Validation in this context does not mean software testing in the standard engineering sense. It means documented evidence, organized according to regulatory expectations, that a system was installed correctly (Installation Qualification), operates as intended (Operational Qualification), and performs reliably under production conditions (Performance Qualification). The GAMP 5 framework from the International Society for Pharmaceutical Engineering (ISPE) is the de facto industry approach to risk-based validation.
Clinical data standards add another layer. Since 2016 (clinical) and 2017 (nonclinical), the FDA has required electronic submissions to use CDISC-compliant data formats: CDASH for data collection, SDTM for study data tabulation, and ADaM for analysis datasets. Choosing clinical data management systems, EDC platforms, and biostatistical tools that support these standards is a technology-strategy decision with direct consequences for submission readiness. A Phase III program that arrives at NDA submission with data that does not conform to CDISC standards faces significant remediation risk at the worst possible moment.
The technology systems that a pharma company's IT strategy has to address include clinical trial management systems (CTMS), electronic data capture (EDC) platforms such as Medidata Rave or Veeva Vault CDMS, electronic trial master file (eTMF) systems, laboratory information management systems (LIMS), manufacturing execution systems (MES), quality management systems (QMS), and regulatory information management (RIM) systems for submission planning and tracking. Each of these carries its own validation requirements, interoperability considerations, and vendor landscape. The technology strategy has to address them as a system, not as independent point solutions.
AI in pharma and life sciences: where governance meets GxP
Artificial intelligence in pharmaceutical and life sciences is moving in two directions simultaneously. The first is AI embedded in products: diagnostic algorithms, drug-discovery models, and companion diagnostics. The second is AI used in the processes that support drug development: trial design optimization, patient enrollment, adverse event signal detection, regulatory submission drafting.
For AI embedded in products, the FDA pathway considerations described in the medtech section apply. For AI used in GxP-regulated processes, the emerging question is how AI tools fit within the existing validation and data integrity framework.
The FDA's current position is that GxP-regulated AI systems require the same rigorous validation and change control as any other GxP computer system, which means that an AI tool used to support a GxP decision cannot simply be deployed and monitored. It has to be validated, and any changes to the model, including retraining, must go through a documented change-control process that assesses their impact on the validated state.
The practical consequence for life sciences companies: the enthusiasm for deploying AI across drug development workflows runs directly into the GxP validation discipline. A technology strategy that treats AI deployment in a pharma context as equivalent to deploying an AI tool in a general enterprise context will result in compliance exposure, validation backlogs, and findings that appear in FDA Warning Letters.
Where HIPAA and health system considerations still apply
Medtech and pharma companies are not exempt from HIPAA when they handle protected health information. A medtech company that processes patient data from its connected device, a pharma company that runs a patient support program, a clinical trial sponsor that holds identifiable participant records: all of these carry HIPAA obligations alongside their FDA regulatory requirements.
Interoperability with health systems is also increasingly a product requirement, not just an IT decision. Medtech devices that need to push data to an EHR, or pull patient records to inform a clinical decision support algorithm, face the same FHIR API and HL7 integration requirements that health system IT teams work with every day. Understanding how those integrations work, what data governance applies, and how the HIPAA and FDA frameworks interact is increasingly the domain of the technology strategist, not just the regulatory lawyer.
What Tristella brings to medtech, pharma, and life sciences IT strategy
Tristella Advisors' healthcare work is grounded in direct operational experience inside the digital health and health technology ecosystem. My background includes roles at ELLKAY, which focuses on healthcare data connectivity and interoperability for clinical laboratories and health plans; Amwell, one of the largest telehealth platforms in the United States; SafelyYou, an AI-powered fall detection platform for memory care that operates in the SaMD-adjacent space; and TransformCare, a care management technology company.
That experience spans the intersection of health system IT, digital health product development, and the regulatory frameworks governing AI-enabled healthcare technology. It is not health system EHR consulting or pharma regulatory affairs consulting. It is the work that happens in between: helping technology companies and life sciences organizations make the technology strategy decisions that determine whether their products and systems are built to operate in a regulated environment from the start.
The specific areas where Tristella's work is most relevant for medtech, pharma, and life sciences organizations:
Technology roadmap and systems strategy for regulated environments. Evaluating and selecting the right clinical data management, QMS, CTMS, eTMF, or digital health platform for a life sciences organization requires understanding how each system performs in a validated environment, how it fits the organization's regulatory context, and what the implementation and validation burden looks like. That work requires both technology depth and regulatory context.
AI governance and readiness. Tristella's Polaris AI Risk Management Framework covers the governance dimensions that a life sciences company deploying AI needs to have in place: AI inventory and risk classification, accountability structure, data practices, output quality and human oversight, third-party AI risk, and incident response. For medtech companies, the Polaris governance design directly informs what a PCCP framework should address. For pharma companies, it maps to the GxP validation and change control requirements that FDA expects for AI used in regulated processes.
Salesforce Life Sciences Cloud and commercial operations technology. Life sciences companies using Salesforce for commercial operations, patient services, and medical affairs have a specific implementation context that differs from that of a standard CRM deployment. Data governance for promotional and scientific exchange, HIPAA-compliant patient data handling, and integration with medical systems require configuration decisions that standard Salesforce implementations do not address. Velma's 15 Salesforce Application Architect certifications and production experience in regulated environments directly support this work.
Organizational change management for technology adoption. GxP and FDA-regulated technology implementations fail most often not because the system was chosen or configured incorrectly, but because the organization was not prepared to operate it correctly. Validation requires operational discipline: trained users, controlled change management, documented deviations, and sustained quality processes. Change management for a life sciences technology implementation is a different discipline from that for an enterprise SaaS rollout, and the gap between the two is where most implementations create their long-term problems.
For medtech, pharma, and life sciences organizations evaluating their technology strategy, the right starting point is a conversation about the specific decisions in front of you, the regulatory context that shapes them, and what the organization needs to do after the engagement that it cannot do now.
Explore our healthcare IT and life sciences advisory services at tristellaadvisors.com/services/healthcare-it, or book an initial conversation at tristellaadvisors.com/contact.
Related reading:
What Does Healthcare IT Strategy Consulting Cost? Fees, Retainers, and What You're Actually Buying
What Does a Healthcare IT Strategy Consultant Do and When Do You Need One?
Which Advisory Firms Handle AI Governance Compliance for Healthcare Organizations?
AI Governance Software vs. AI Governance Consulting: What Your Organization Actually Needs
Sources: